Trends in Immunotherapy

Review

Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy

Downloads

https://doi.org/10.24294/ti.v7.i1.1838
Sivalingam, D., & Singh, M. (2023). Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy. Trends in Immunotherapy, 7(1). https://doi.org/10.24294/ti.v7.i1.1838
Volume 7 Issue 1 (2023)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Dillon Sivalingam Nano-Gene and Drug Delivery Group, Discipline of Biochemistry, University of KwaZulu-Natal
  • Moganavelli Singh
    Nano-Gene and Drug Delivery Group, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag X54001, Durban, South Africa

The angiotensin-converting enzyme 2 (ACE2) receptor gained prominence in 2020, having been identified as a prime receptor for entry of the novel coronavirus COVID-19, which has led to the current global pandemic. Many stud-ies have reported that lung cancer patients have a higher risk of contracting COVID-19 due to the up-regulated expres-sion of ACE2 in lung cancer cells. Lung cancer is a heterogeneous disease and the most frequently occurring cancer globally. It is more prevalent in men than in women and accounts for an estimated 40% of cancer cases. Over the years, many studies have reported on the ACE2 expression in lung cancer. Conventional methods currently available for the detection and treatment of lung cancer face numerous challenges. Nanomedicine has risen to many challenges facing cancer therapy and drug delivery. With the array of nano delivery systems available, nanomedicine can be used to de-velop alternative methods to help overcome these challenges and improve the therapeutic efficiency in cancer therapy. Hence, this review focuses on lung cancer, the ACE2 receptor, and the use of nanomedicine in formulating a novel tar-geted cancer treatment strategy directed at the ACE2 receptor. This may serve as a stepping stone for exploring further targeting strategies and therapies.

Keywords:

ACE2 Receptor Nanomedicine Lung Cancer Therapy Targeting

References

  1. World Health Organization [Internet]. 2022 [cited 2022 Aug 1]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
  2. Bade BC, Cruz CSD. Lung cancer 2020: Epidemiology, etiology, and prevention. Clinics in Chest Medicine 2020; 41: 1–24. doi: 10.1016/j.ccm.2019.10.001.
  3. Mao Y, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. Surgical Oncology Clinics 2016; 25: 439–445. doi: 10.1016/j.soc.2016.02.001.
  4. Woodman C, Vundu G, George A, Wilson CM. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Seminars in Cancer Biology 2021; 69: 349–364. doi: 10.1016/j.semcancer.2020.02.009.
  5. Hussain S. Nanomedicine for treatment of lung cancer. Advances in Experimental Medicine and Biology 2015; 890: 137–147. doi: 10.1007/978-3-319-24932-2_8.
  6. Chai P, Yu J, Ge S, et al. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: A pan-cancer analysis. Journal of Hematology and Oncology 2020; 13: 1–5 doi: 10.1186/s13045-020-00883-5.
  7. Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target—A perspective. Endocrine, Metabolic & Immune Disorders-Drug Targets 2020; 20: 807–811. doi: 10.2174/1871530320666200427112902.
  8. Zhang H, Penninger J, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Medicine 2020; 46: 586–590. doi: 10.1007/s00134-020-05985-9.
  9. Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and molecular classification of lung cancer. Cancer Treatment and Research 2016; 170: 25–46. doi: 10.1007/978-3-319-40389-2_2.
  10. Gariani J, Martin SP, Hachulla AL, et al. Non-invasive pulmonary nodule characterization using transcutaneous bioconductance: Preliminary results of an observational study. Medicine (Baltimore) 2018; 97: e11924. doi: 10.1097/MD.000000000001192.
  11. Dong S, Men W, Yang S, Xu S. Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples. Oncology Reports 2020; 43: 1437–1450. doi: 10.3892/or.2020.7526.
  12. Byun J, Schwartz AG, Lusk C, et al. Genome-wide association study of familial lung cancer. Carcinogenesis 2018; 39: 1135–1140. doi: 10.1093/carcin/bgy080.
  13. Pascoe HM, Knipe HC, Pascoe D, et al. The many faces of lung adenocarcinoma: A pictorial essay. Journal of Medical Imaging and Radiation Oncology 2018; 62: 654–661. doi: 10.1111/1754-9485.12779.
  14. Xu JY, Zhang C, Wang X, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 2020; 182: 245–261. doi: 10.1016/j.cell.2020.05.043.
  15. Samad A, Jafar T, Rafi JH. Identification of angiotensin-converting enzyme 2 (ACE2) protein as the potential biomarker in SARS-CoV-2 infection-related lung cancer using computational analyses. Genomics 2020; 112: 4912–4923. doi: 10.1016/j.ygeno.2020.09.002.
  16. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581: 215–220. doi: 10.1038/s41586-020-2180-5.
  17. Gross LZF, Sacerdoti M, Piiper A, et al. ACE2, the receptor that enables the infection by SARS‐CoV‐2: Biochemistry, structure, allostery and evaluation of the potential development of ACE2 modulators. ChemMedChem 2020; 15: 1682–1690. doi: 10.1002/cmdc.202000368.
  18. Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Frontiers in Cellular and Infection Microbiology 2020; 10: 317. doi: 10.3389/fcimb.2020.00317.
  19. Albini A, Di Guardo G, Noonan DM, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: Implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies. Internal and Emergency Medicine 2020; 15: 759–766. doi: 10.1007/s11739-020-02364-6.
  20. Camargo SM, Vuille-dit-Bille RN, Meier CF, Verrey F. ACE2 and gut amino acid transport. Clinical Science 2020; 134: 2823–2833. doi: 10.1042/CS20200477.
  21. Ziegler CG, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020; 181: 1016–1035.doi:10.1016/j.cell.2020.04.035.
  22. Jagaran K, Singh M. Nanomedicine for neurodegenerative disorders: Focus on Alzheimer’s and Parkinson’s diseases. International Journal of Molecular Sciences 2021; 22: 9082. doi: 10.3390/ijms22169082.
  23. Maney V, Singh M. An in vitro assessment of Chitosan/Bimetallic PtAu nanocomposites as delivery vehicles for Doxorubicin. Nanomedicine 2017; 12: 2625–2640. doi: 10.2217/nnm-2017-0228.
  24. Cryer AM, Thorley AJ. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacology and Therapeutics 2019; 198: 189–205. doi: 10.1016/j.pharmthera.2019.02.010.
  25. Daniels AN, Singh M. Sterically stabilized siRNA: Gold nanocomplexes enhance c-MYC silencing in a breast cancer cell model. Nanomedicine 2019; 14: 1387–1401. doi: 10.2217/nnm-2018-0462.
  26. Mbatha LS, Singh M. Starburst poly (amidoamine) dendrimer grafted gold nanoparticles as a scaffold for folic acid-targeted plasmid DNA delivery in vitro. Journal of Nanoscience and Nanotechnology 2019; 19: 1959–1970. doi: 10.1166/jnn.2019.15798.
  27. Akinyelu J, Singh M. Chitosan stabilized gold-folate-poly(lactide-co-glycolide) nanoplexes facilitate efficient gene delivery in hepatic and breast cancer cells. Journal of Nanoscience and Nanotechnology 2018; 18: 4478–4486. doi: 10.1166/jnn.2018.15286.
  28. Noorbazargan H, Amintehrani S, Dolatabadi A, et al. Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells. AMB Express 2021; 11: 1–14. doi: 10.1186/s13568-021-01216-6.
  29. Gounden S, Daniels A, Singh M. Chitosan-modified silver nanoparticles enhance cisplatin activity in breast cancer cells. Biointerface Research in Applied Chemistry 2021; 11: 10572–10584. doi: 10.33263/BRIAC113.1057210584.
  30. Olawale F, Ariatti M, Singh M. Ocimum tenuiflorum L mediated green synthesis of silver and selenium nanoparticles: Antioxidant activity, cytotoxicity and density functional theory studies. Advances in Natural Sciences: Nanoscience and Nanotechnololgy 2022; 13: 015015. doi: 10.1088/2043-6262/ac5d4a/meta.
  31. He Y, Du Z, Ma S, et al. Effects of green-synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo. International Journal of Nanomedicine 2016; 11: 1879–1887. doi: 10.2147%2FIJN.S103695.
  32. Tian J, Wei X, Zhang W, et al. Effects of selenium nanoparticles combined with radiotherapy on lung cancer cells. Frontiers in Bioengineering and Biotechnology 2020; 8: 598997. doi: 10.3389/fbioe.2020.598997.
  33. Zou J, Su S, Chen Z, et al. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy. Artificial Cells, Nanomedicine and Biotechnology 2019; 47: 3456–3464. doi: 10.1080/21691401.2019.1626863.
  34. Singh D, Singh M. Hepatocellular-targeted mRNA delivery using functionalized selenium nanoparticles in vitro. Pharmaceutics 2021; 13: 298. doi: 10.3390/pharmaceutics13030298.
  35. Maiyo F, Singh M. Selenium nanoparticles: Potential in cancer gene and drug delivery. Nanomedicine 2017; 12: 1075–1089. doi: 10.2217/nnm-2017-0024.
  36. Ameh T, Sayes CM. The potential exposure and hazards of copper nanoparticles: A review. Environmental Toxicology and Pharmacology 2019; 71: 103220. doi: 10.1016/j.etap.2019.103220.
  37. Jagaran K, Singh M. Nanomedicine for COVID-19: Potential of copper nanoparticles. Biointerface Research in Applied Chemistry 2021; 11: 10716–10728. doi: 10.33263/BRIAC113.1071610728.
  38. Kalaiarasi A, Sankar R, Anusha C, et al. Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. Biotechnology Letters 2018; 40: 249–256. doi: 10.1007/s10529-017-2463-6.
  39. Venkatas J, Singh M. Nanomedicine-mediated optimization of immuno-therapeutic approaches in cervical cancer. Nanomedicine 2021; 16: 1311–1328. doi: 10.2217/nnm-2021-0044.
  40. Rajeshkumar S. Anticancer activity of eco-friendly gold nanoparticles against lung and liver cancer cells. Journal of Genetic Engineering and Biotechnology 2016; 14: 195–202. doi: 10.1016/j.jgeb.2016.05.007.
  41. Abbas G, Kumar N, Kumar D, Pandey G. Effect of reaction temperature on shape evolution of palladium nanoparticles and their cytotoxicity against A-549 lung cancer cells. ACS Omega 2019; 4: 21839–21847. doi: 10.1021/acsomega.9b02776.
  42. Kumari R, Saini AK, Kumar A, Saini RV. Apoptosis induction in lung and prostate cancer cells through silver nanoparticles synthesized from Pinus roxburghii bioactive fraction. Journal of Biological Inorganic Chemistry 2020; 25: 23–37. doi: 10.1007/s00775-019-01729-3.
  43. ClinicalTrials.gov [Internet]. [cited 2022 Jul 15]. Available from: https://www.clinicaltrials.gov/ct2/results?cond=%20Lung%20+cancer&term=nanoparticles&cntry=&state=&city=&dist=&Search=Search.